Bioxcel Therapeutics Inc (BTAI)

May 14, 2025

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 14, 2025

May 13, 2025

BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments - TipRanks

May 13, 2025

May 12, 2025

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | BTAI Stock News - GuruFocus

May 12, 2025

May 12, 2025

BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025

May 12, 2025

BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025

May 12, 2025

BioXcel Therapeutics (BTAI) Reports Major Milestone in BXCL501 T - GuruFocus

May 12, 2025

May 12, 2025

BioXcel Therapeutics Q1 2025 Financial Results and Business Update - TradingView

May 12, 2025

May 12, 2025

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 12, 2025

May 09, 2025

BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options - The Globe and Mail

May 09, 2025

May 06, 2025

SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

May 06, 2025

May 02, 2025

IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - The Malaysian Reserve

May 02, 2025

Apr 30, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 30, 2025

Apr 29, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of BioXcel Therapeutics, Inc.(BTAI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 29, 2025

Apr 28, 2025

Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.

Apr 28, 2025

Apr 06, 2025

BioXcel Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Apr 06, 2025

Apr 05, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 By Investing.com - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

BioXcel Therapeutics stock hits 52-week low at $1.72 - Investing.com

Apr 04, 2025

Apr 04, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program - Investing.com Australia

Apr 04, 2025

Apr 03, 2025

BioXcel Therapeutics Initiates At-The-Market Equity Program By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 03, 2025

Bioxcel Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $8.1 Million From Time To Time Through CanaccordSEC Filing - MarketScreener

Apr 03, 2025

Apr 02, 2025

ROSEN, A RANKED AND LEADING FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BTAI - AsiaOne

Apr 02, 2025

Mar 29, 2025

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 29, 2025

Mar 29, 2025

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo

Mar 29, 2025

Mar 28, 2025

BioXcel Therapeutics Advances Clinical Trials and Reduces Losses - TipRanks

Mar 28, 2025

Mar 28, 2025

BioXcel Therapeutics Inc. (BTAI) reports earnings - Quartz

Mar 28, 2025

Mar 28, 2025

BioXcel Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 28, 2025

Mar 27, 2025

BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

BioXcel Therapeutics, Inc. Q4 Loss Declines - Nasdaq

Mar 27, 2025

Mar 27, 2025

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewswire

Mar 27, 2025

Mar 26, 2025

Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 26, 2025

Mar 22, 2025

BioXcel Therapeutics faces potential Nasdaq delisting By Investing.com - Investing.com India

Mar 22, 2025

Mar 22, 2025

BioXcel Therapeutics (NASDAQ:BTAI) Upgraded at RODMAN&RENSHAW - Defense World

Mar 22, 2025

Mar 21, 2025

BioXcel Therapeutics faces potential Nasdaq delisting - Investing.com

Mar 21, 2025

Mar 21, 2025

BIOXCEL THERAPEUTICS INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 21, 2025

Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

BioXcel Therapeutics reports progress in Phase 3 trial - Investing.com India

Mar 21, 2025

Mar 19, 2025

Rodman & Renshaw Initiates Coverage of BioXcel Therapeutics (BTAI) with Buy Recommendation - Nasdaq

Mar 19, 2025

Mar 19, 2025

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight - Nasdaq

Mar 19, 2025

Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

BioXcel Therapeutics boosts cash to $35M for Phase 3 trial By Investing.com - Investing.com South Africa

Mar 11, 2025